Epilepsy Drug for Sleep Apnea

Epilepsy drug for sleep apnea refers to the repurposing of sulthiame, a carbonic anhydrase inhibitor originally developed for epilepsy, as a pharmacological treatment for obstructive sleep apnea in adults who cannot tolerate CPAP therapy. According to a phase 2b clinical trial led by researchers at the University of Gothenburg, sulthiame reduced breathing interruptions by roughly 20 to 30 percent and improved overnight oxygen levels compared to placebo. This article is for health-conscious adults, longevity-focused individuals tracking biological age, wearable users, and anyone exploring alternatives to continuous positive airway pressure therapy. It covers how sulthiame works at the molecular level, who it may help, its side effects, how it compares to CPAP and oral appliances, and why sleep apnea treatment matters for long-term biological aging. If you have been told you need CPAP but struggle with adherence, what follows could reshape your options.

Quick Answer

Sulthiame is an epilepsy medication now being studied as a drug treatment for obstructive sleep apnea. A phase 2b clinical trial led by Jan Hedner at the University of Gothenburg found that sulthiame reduced the apnea-hypopnea index and improved oxygen saturation overnight in adults with moderate to severe sleep apnea. It works by inhibiting carbonic anhydrase, which stabilizes respiratory control during sleep. The drug is not yet approved for sleep apnea treatment in the United States. Dumbo Health does not prescribe sulthiame. It offers a $149 at-home sleep apnea test and CPAP care in Florida, Texas, Virginia and Maryland, plus a sleep longevity membership for tracking biomarkers.

Key Takeaways

• Sulthiame is a carbonic anhydrase inhibitor used for decades in epilepsy that has shown meaningful reductions in breathing interruptions during sleep in a rigorous clinical trial
• The phase 2b trial enrolled 298 adults across European countries including Germany, Belgium, Czech Republic, France, and Spain, and measured outcomes using polysomnography
• The trial met its main goal at all three doses: the apnea-hypopnea index fell compared to placebo (by about 16 to 35 percent depending on dose, with bigger drops at higher doses), and overnight oxygen levels improved
• CPAP therapy remains the gold-standard treatment, but real-world adherence rates are estimated at 50 to 70 percent, creating a genuine need for pharmacological alternatives
• Dumbo Health's at-home sleep apnea test costs $149 with physician diagnosis typically within 48 hours, (available in Florida, Texas, Virginia and Maryland)
• Side effects of sulthiame include tingling sensations, headaches, fatigue, and nausea, most of which were mild to moderate in the trial

What Sulthiame Is and Why an Epilepsy Drug Matters for Sleep Apnea

Sulthiame is a carbonic anhydrase inhibitor that has been prescribed under the brand name Ospolot for epilepsy treatment in European countries since the 1960s. Its relevance to obstructive sleep apnea lies in how it affects respiratory control at the brainstem level.

Carbonic anhydrase is an enzyme that regulates the conversion of carbon dioxide and water to bicarbonate and hydrogen ions throughout the body, including in the brain and kidneys. When this enzyme is inhibited, the body's chemoreceptors become more sensitive to carbon dioxide buildup during sleep. That increased sensitivity means the brain sends stronger signals to keep the upper airway muscles active and breathing stable, even during the deepest phases of non-REM sleep and REM sleep when muscle tone naturally drops.

Obstructive sleep apnea occurs when the upper airway muscles relax enough to cause partial or complete airway collapse during sleep, leading to repeated respiratory pauses, oxygen desaturation, and sleep fragmentation. The standard explanation for these events involves a combination of anatomical factors (such as upper airway volume, tonsil grading, and Mallampati classification) and physiological traits described in the PALM scale: Pharyngeal critical closing pressure, Arousal threshold, Loop gain, and muscle responsiveness.

Sulthiame primarily targets Loop gain, which describes how aggressively the brain's respiratory control system responds to changes in blood gases. By increasing the ventilatory drive through carbonic anhydrase inhibition, sulthiame helps stabilize breathing and reduce the frequency of airway collapsing events during sleep.

DID YOU KNOW: Carbonic anhydrase inhibitors have been studied in respiratory medicine for decades. Acetazolamide, another drug in this class, has been used at altitude to prevent periodic breathing, which shares physiological overlap with obstructive sleep apnea.

KEY TAKEAWAY: Sulthiame works by inhibiting carbonic anhydrase, which increases the brain's sensitivity to carbon dioxide and stabilizes respiratory control during sleep, directly addressing one of the core physiological mechanisms behind obstructive sleep apnea.

Understanding the clinical evidence behind sulthiame requires a closer look at the pivotal trial that brought this epilepsy medication into the sleep apnea conversation.

The Phase 2b Clinical Trial: What Jan Hedner's Team Found

The most important clinical evidence for sulthiame as a sleep apnea treatment comes from a phase 2b trial led by Jan Hedner, a professor of pulmonary medicine at the University of Gothenburg and Sahlgrenska University Hospital in Gothenburg, Sweden. The results were first presented at the European Respiratory Society Congress in 2024.

Trial Design and Population

The trial enrolled 298 adults with moderate to severe obstructive sleep apnea across clinical sites in five European countries: Belgium, Czech Republic, France, Germany, and Spain. All participants had either refused CPAP therapy, failed to tolerate it, or were considered unsuitable candidates for continuous positive airway pressure.

Participants were randomized into four groups: three different doses of sulthiame (100 mg, 200 mg, and 300 mg taken daily) and one placebo group. The trial ran for 12 weeks. The primary outcome measure was the change in AHI4, defined as the apnea-hypopnea index using a 4 percent oxygen desaturation threshold, measured by full in-lab polysomnography at baseline and at the end of treatment.

Key Results

The trial met its primary goal at all three doses: each dose reduced the apnea-hypopnea index significantly compared to placebo, with larger reductions at the higher doses. Compared with placebo, the reduction was about 16 percent at 100 mg, 30 percent at 200 mg and 35 percent at 300 mg. This is a meaningful but moderate effect. For context, CPAP therapy typically reduces AHI by 80 to 95 percent in adherent users.

Beyond the apnea/hypopnea index, sulthiame also improved overnight oxygen levels. Participants showed less oxygen desaturation and fewer episodes of hypoxemia during sleep. The mean oxygen saturation improved, and the time spent with blood oxygen below critical thresholds decreased.

The trial also assessed daytime sleepiness using the Epworth Sleepiness Scale, a validated questionnaire that rates subjective drowsiness. There was a trend toward improvement in sleepiness scores, though the primary endpoint was respiratory, not symptom-based.

What the Results Mean in Context

A 20 to 30 percent reduction in breathing interruptions is clinically relevant for patients who cannot use CPAP, but it does not replace CPAP therapy for people who can tolerate it. The European Respiratory Society noted that these findings represent a promising step toward pharmacologically treating obstructive sleep apnoea, while acknowledging that further phase 3 trials are needed before regulatory approval.

Jan Hedner and colleagues emphasized that sulthiame is not intended as a first-line replacement for positive airway pressure therapy but rather as an option for the large population of adults who struggle with mask-based treatment. According to various adherence studies, roughly 30 to 50 percent of CPAP users abandon therapy within the first year, making alternative treatments a genuine clinical priority.

Sulthiame is not currently approved for sleep apnea treatment in the United States or Europe. It remains an investigational drug for this indication, and additional clinical trials are required before it could become available as a prescribed sleep apnea medication.

KEY TAKEAWAY: The phase 2b trial demonstrated that sulthiame can reduce the apnea-hypopnea index by roughly 20 to 30 percent and improve oxygen levels overnight, but the drug remains investigational and does not match the effectiveness of CPAP therapy in people who tolerate it.

Knowing what sulthiame can do requires understanding how it compares to the treatments already available.

How Sulthiame Compares to CPAP, Oral Appliances, and Lifestyle Modifications

CPAP therapy remains the gold standard for obstructive sleep apnea, but it is only one of several treatment options. Understanding where sulthiame fits requires comparing it against the interventions that exist right now.

Effectiveness at Reducing AHI

• Sulthiame (investigational): about 16 to 35 percent reduction in apnea-hypopnea index versus placebo in the phase 2b trial, depending on dose
• CPAP therapy: approximately 80 to 95 percent reduction in AHI when used correctly and consistently
• Oral appliances (mandibular advancement devices): approximately 40 to 60 percent reduction in AHI depending on severity, according to the American Academy of Sleep Medicine

How Treatment Is Delivered

• Sulthiame: daily oral tablet taken before bed, no equipment required
• CPAP therapy: continuous positive airway pressure delivered through a mask worn during sleep
• Oral appliances: custom-fitted dental device worn during sleep to advance the jaw and prevent airway collapse

Adherence and Convenience

• Sulthiame: high convenience (oral medication), but potential side effects may affect adherence in some users
• CPAP therapy: highly effective when used, but the Sleep Foundation and multiple studies document that 30 to 50 percent of users discontinue therapy within the first year due to mask discomfort, claustrophobia, or lifestyle incompatibility
• Oral appliances: moderate convenience, but require dental fitting and may cause jaw discomfort or bite changes over time

Side Effect Profile

• Sulthiame: tingling in the extremities (paresthesia), headaches, fatigue, nausea, and in rare cases taste disturbance. The phase 2b trial reported most side effects as mild to moderate. Because sulthiame is an antiepileptic medication, there is also a theoretical concern about effects on cortical excitability, though no seizures were reported in the sleep apnea trial population.
• CPAP therapy: nasal dryness, skin irritation from the mask, aerophagia (swallowing air), and disrupted sleep for bed partners
• Oral appliances: jaw pain, excessive salivation, and potential long-term dental changes

Best For

• Sulthiame: adults with moderate to severe obstructive sleep apnea who cannot tolerate CPAP or oral appliances, once the drug receives regulatory approval
• CPAP therapy: anyone with moderate to severe sleep apnea who can adhere to nightly mask use
• Oral appliances: adults with mild to moderate sleep apnea, or those with moderate severity who refuse CPAP

For people currently managing or being diagnosed with sleep apnea, the starting point is an accurate diagnosis. Dumbo Health's at-home sleep apnea test costs $149, uses an FDA-cleared device, and delivers physician-reviewed results typically within 48 hours, giving you a clear AHI score and oxygen desaturation data before any treatment decision.

KEY TAKEAWAY: Sulthiame offers a genuinely new treatment category for sleep apnea as an oral medication, but its moderate AHI reduction means it is best positioned for patients who cannot use CPAP rather than as a replacement for those who can.

Beyond comparing treatments, the physiological mechanisms that connect sleep apnea to biological aging help explain why getting the right diagnosis and treatment matters far beyond nighttime comfort.

Why Sleep Apnea Treatment Is a Longevity Issue, Not Just a Sleep Issue

Untreated obstructive sleep apnea accelerates biological aging through multiple overlapping pathways, making effective treatment one of the most impactful interventions available for slowing age-related decline.

The Biological Aging Cascade of Untreated Sleep Apnea

Each episode of airway collapse during sleep triggers a cascade that reaches far beyond the upper airway. When breathing stops, blood oxygen drops (hypoxemia), the brain triggers a micro-arousal to restore airflow, and the cycle repeats. In moderate to severe cases, this happens 15 to 60 or more times per hour throughout the night.

This pattern of intermittent hypoxia, sometimes called chronic episodic hypoxia, activates inflammatory processes at the cellular level. According to the NIH, intermittent hypoxia upregulates cytokines including TNF-alpha and IL-6, which are the same inflammatory markers associated with accelerated biological aging, cardiovascular disease, and metabolic syndrome.

The downstream consequences are measurable:

• Blood pressure: The CDC notes a strong association between untreated sleep apnea and hypertension, with some studies suggesting that more than 50 percent of people with resistant hypertension have undiagnosed obstructive sleep apnea
• Metabolic health: Intermittent hypoxia disrupts insulin signaling, contributing to insulin resistance and elevated HbA1c. Research published on PubMed has documented links between sleep apnea severity and fasting glucose dysregulation through oxygen sensing pathways and AMPK/mTOR signal pathway disruption
• Cardiovascular risk: Repeated oxygen desaturation and sympathetic nervous system activation alter heart rhythm and increase the risk of atrial fibrillation, stroke, and heart failure
• Brain health: Sleep fragmentation disrupts sleep micro-architecture, reducing the restorative phases of non-REM sleep and REM sleep that are critical for hippocampus-dependent memory consolidation, synaptic pruning, and clearance of neurotoxic proteins. Chronic sleep deprivation from untreated sleep apnea has been associated with measurable changes in brain activity and accelerated brain volume loss in the neocortex

At the cellular and molecular level, researchers have identified mitochondrial involvement in the damage caused by intermittent hypoxia. Oxygen-starved cells undergo increased apoptosis (programmed cell death), particularly in oxygen-sensitive tissues. These cellular and molecular mechanisms, along with behavioral and anatomical correlates of chronic sleep disruption, are now understood to contribute directly to the gap between chronological age and biological age.

Where SleepLongevityAge Fits

This is precisely why Dumbo Health built its longevity program around sleep as a biological aging driver. The proprietary SleepLongevityAge metric combines blood biomarkers with optional wearable data from devices like Oura, Whoop, and Garmin to quantify how sleep is accelerating or slowing your biological aging. A person with untreated sleep apnea and elevated hs-CRP, disrupted cortisol patterns, and rising HbA1c is not just sleeping poorly. They are aging faster.

The sleep longevity membership tracks these markers over time, giving members a longitudinal view of how treatment, whether CPAP, medication, or lifestyle modifications, is actually affecting the aging process at the biomarker level. The Core plan tests 51 sleep-longevity biomarkers twice a year for $0.99 a day for early members, providing the data foundation to measure whether interventions are working.

TIP: If you are weighing treatment options for sleep apnea, tracking biomarkers like hs-CRP, HbA1c, cortisol, and ApoB before and after treatment gives you objective evidence of whether your chosen therapy is reducing the biological aging effects of sleep disruption.

KEY TAKEAWAY: Untreated sleep apnea is a driver of biological aging through inflammatory, metabolic, cardiovascular, and neurological pathways, making accurate diagnosis and effective treatment a longevity priority, not just a quality of life improvement.

Understanding the biological stakes helps contextualize why measuring the right biomarkers matters alongside any sleep apnea treatment.

The Science Behind Carbonic Anhydrase Inhibition and Respiratory Control

Carbonic anhydrase inhibition stabilizes breathing during sleep by increasing the brain's sensitivity to rising carbon dioxide levels, which is the core pharmacological mechanism behind sulthiame's effect on obstructive sleep apnea.

How Respiratory Control Works During Sleep

During wakefulness, breathing is regulated by both voluntary and automatic systems. During sleep, voluntary control drops away and the brainstem takes over entirely. The brainstem's respiratory centers in the medulla monitor blood carbon dioxide levels through central and peripheral chemoreceptors. When CO2 rises, the brain increases ventilatory drive, contracting the diaphragm and activating upper airway muscles to keep the airway open.

In people with obstructive sleep apnea, this system is often unstable. The concept of Loop gain describes this instability. A person with high Loop gain has a respiratory control system that overreacts to small changes in CO2, leading to cycles of hyperventilation followed by central pauses, which can then trigger obstructive events when the upper airway muscles fail to maintain patency.

What Carbonic Anhydrase Inhibition Does

Carbonic anhydrase catalyzes the reaction between CO2 and water to form bicarbonate. By inhibiting this enzyme, sulthiame causes a mild metabolic acidosis, which means slightly elevated CO2 levels in the blood. This does two things:

1. It raises the baseline ventilatory drive, meaning the brain sends stronger breathing signals even at rest
2. It narrows the gap between the current CO2 level and the apnea threshold (the CO2 level below which breathing stops), making it harder for the system to cross into apnea

This pharmacological action is distinct from what CPAP does. Continuous positive airway pressure mechanically splints the airway open with pressurized air, preventing airway collapsing regardless of the brain's respiratory drive. Sulthiame instead works on the neural and chemical side, making the brain less likely to let breathing become unstable in the first place.

Relevance to EEG Power Spectra and Sleep Architecture

One underappreciated aspect of carbonic anhydrase inhibitors is their effect on sleep micro-architecture. Early research has suggested that drugs in this class may alter EEG power spectra during sleep, potentially increasing slow-wave activity in non-REM sleep. If confirmed in larger trials, this would mean sulthiame could improve not just the apnea-hypopnea index but also the restorative quality of sleep itself.

Because sulthiame originated as an antiepileptic medication used to reduce cortical excitability and control seizures, its effects on brain activity are complex. In epilepsy, the drug suppresses abnormal neuronal firing. In the sleep apnea context, researchers are still investigating whether this modulation of cortical excitability contributes to changes in arousal threshold, which is another key variable in the PALM scale that determines how easily a person wakes up during a breathing event.

KEY TAKEAWAY: Carbonic anhydrase inhibition addresses obstructive sleep apnea through a fundamentally different mechanism than CPAP by stabilizing the brain's respiratory control system rather than mechanically holding the airway open.

The mechanism is promising, but like all medications, sulthiame carries specific risks and limitations worth understanding.

Side Effects, Safety Profile, and Limitations of Sulthiame for Sleep Apnea

Sulthiame's side effects were mostly mild to moderate in the phase 2b trial, but several important limitations make it unsuitable for certain populations and insufficient as a standalone treatment for severe cases.

Known Side Effects from the Clinical Trial

The most commonly reported side effects in the phase 2b trial included:

• Paresthesia (tingling or numbness in the hands, feet, or face), reported in a significant proportion of participants, particularly at the 300 mg dose
• Headaches, which were more common in the sulthiame groups than in placebo
• Fatigue, which is notable because the drug is being used to treat a condition that already causes excessive daytime sleepiness
• Nausea and gastrointestinal discomfort
• Taste disturbance, described as a metallic or altered taste

Most side effects were described as mild to moderate in the trial's safety profile analysis. No serious adverse events directly attributable to sulthiame were reported. Importantly, no seizures were triggered in the sleep apnea trial population, even though the drug's primary indication is epilepsy and it directly affects cortical excitability.

Limitations and Risks

Not every person with obstructive sleep apnea is a candidate for sulthiame, and several limitations are important to understand:

1. Moderate efficacy compared to CPAP. A 20 to 30 percent AHI reduction is meaningful but leaves substantial residual disease in people with severe obstructive sleep apnea. Someone with an AHI of 50 events per hour would still have 35 to 40 events per hour on sulthiame, which remains clinically significant.
2. Not yet approved for sleep apnea. At the time of writing, sulthiame is an investigational drug for this indication. No phase 3 trial has been announced yet, and one would be needed, and regulatory approval in the United States has not been granted. Patients cannot obtain a prescription for sulthiame specifically for sleep apnea through standard clinical channels.
3. Unknown long-term safety for this population. While sulthiame has decades of safety data in epilepsy patients, chronic use in a broader population of adults with sleep apnea and common comorbidities like hypertension, metabolic syndrome, and cardiovascular disease has not been studied beyond 12 weeks.
4. Medical instability exclusions. The trial excluded participants with significant medical instability, severe cardiac disease, and other conditions. It is unclear how sulthiame would perform in the real-world population of sleep apnea patients, many of whom have multiple comorbidities.
5. Does not address anatomical causes. For patients whose sleep apnea is primarily driven by anatomical factors like large tonsils (kissing tonsils), low upper airway volume, or high Mallampati classification scores, a medication that targets respiratory control may provide limited benefit. These patients may require surgical intervention or mechanical therapy.
6. Interaction with other medications. As a carbonic anhydrase inhibitor that causes metabolic acidosis, sulthiame may interact with other medications that affect acid-base balance, kidney function, or electrolyte levels. Physician oversight is essential.

How Dumbo Health Helps Navigate These Limitations

For people exploring their sleep apnea treatment options, the first step is always an accurate diagnosis with clear severity data. Dumbo Health provides an at-home sleep apnea test for $149 that delivers your AHI score, oxygen desaturation data, and physician review typically within 48 hours. With that data, you and your clinician can determine whether CPAP therapy, an oral appliance, lifestyle modifications, or potentially a future pharmacological option like sulthiame is the right fit.

For people already on CPAP who want to understand how well their therapy is working at the biological level, the sleep longevity assessment provides a starting point to evaluate whether your current treatment is actually reversing the aging effects of sleep apnea.

KEY TAKEAWAY: Sulthiame's side effects are mostly mild, but the drug's moderate efficacy, investigational status, and unknown long-term safety in sleep apnea patients mean it is not a replacement for CPAP and requires careful clinical context before considering it as an option.

Limitations aside, understanding who would benefit most from a pharmacological sleep apnea treatment helps put sulthiame's potential into practical perspective.

Who Could Benefit: Real-World Scenarios for Pharmacological Sleep Apnea Treatment

The potential for an epilepsy drug to treat sleep apnea matters most to specific groups of people facing real barriers with existing therapies.

Common Scenarios

A 48-year-old project manager who was diagnosed with moderate obstructive sleep apnea (AHI of 22) tried CPAP for four months and consistently removed the mask within two hours of falling asleep. Despite trying three different mask types, she found the sensation of positive airway pressure intolerable. Her Epworth Sleepiness Scale score remained elevated at 14, and she noticed worsening fatigue, difficulty concentrating, and rising blood pressure at her last physical. For someone in this position, a medication like sulthiame could reduce her AHI by approximately 5 to 7 points, potentially moving her from moderate to mild severity, while she pursues additional interventions like weight management and positional therapy.

A 55-year-old long-haul truck driver was flagged for sleep apnea testing during a DOT physical due to a BMI over 35 and a neck circumference above 17 inches. His polysomnography showed severe obstructive sleep apnea with an AHI of 45 and significant oxygen desaturation, with overnight oxygen levels dropping below 85 percent more than 20 times per hour. For this individual, sulthiame alone would be insufficient. CPAP therapy with high adherence is the clinical recommendation. His starting point would be getting an accurate home sleep apnea test and working with a physician to build a treatment plan.

A 39-year-old wearable enthusiast tracks her sleep with an Oura ring and has noticed progressively worsening deep sleep percentages and rising resting heart rate over the past year. She does not snore loudly and has no classic obstructive sleep apnea symptoms, but a biomarker panel through Dumbo Health's Core membership reveals elevated hs-CRP, an unexplained upward trend in HbA1c, and a SleepLongevityAge score that is 6 years older than her chronological age. A clinical workup including polysomnography reveals upper-airway resistance syndrome with an AHI of 8 but significant respiratory effort-related arousals. For her, a carbonic anhydrase inhibitor like sulthiame might eventually be appropriate as part of a multimodal approach, but today the first step is understanding her complete biomarker profile and tracking changes over time.

Why Scenarios Like These Matter for Treatment Decisions

These examples illustrate that sleep apnea is not one condition with one solution. The interplay between anatomical factors (upper airway muscles, tonsil grading, airway collapse patterns), physiological traits (Loop gain, arousal threshold, muscle responsiveness), and systemic health consequences (inflammation, metabolic dysfunction, cardiovascular strain) means treatment must be personalized.

Dumbo Health's approach of combining diagnostic sleep testing with longitudinal biomarker tracking through the sleep longevity program gives people the data they need to make informed treatment choices rather than relying on a one-size-fits-all recommendation.

KEY TAKEAWAY: A pharmacological sleep apnea treatment like sulthiame would serve a real clinical need for CPAP-intolerant patients, but the right treatment depends on individual severity, anatomy, and systemic health markers that can be tracked over time.

To get an accurate picture of where you stand, the testing and onboarding process is straightforward.

How to Get Tested and Start Tracking Sleep Apnea's Impact on Your Biological Age

Getting a clear diagnosis and connecting it to biological aging markers requires a defined sequence of steps, not guesswork.

Step-by-Step Process

1. Take the free online Dumbo Health sleep quiz to identify your sleep type, risk factors, and whether further testing is indicated.
2. Order the at-home sleep apnea test for $149 if clinical screening suggests obstructive sleep apnea (available in Florida, Texas, Virginia and Maryland). The test uses an FDA-cleared device shipped to your home, requires no in-lab polysomnogram for initial screening, and measures apnea-hypopnea index, oxygen desaturation, heart rhythm, and respiratory patterns.
3. Receive physician-reviewed results typically within 48 hours. Your report includes your AHI score, oxygen levels overnight, and a clinical interpretation from a doctor.
4. Enroll in the sleep longevity membership to establish your biomarker baseline. Book your blood draw through the Quest Diagnostics network at Dumbo Health testing locations, with more than 2,000 locations nationwide and roughly 9 in 10 people living within 20 minutes of a draw site near you.
5. Receive your SleepLongevityAge score, built from your blood biomarkers and optional wearable data, within about 7 days of your blood draw. This score shows where your biological age stands relative to your chronological age and which markers are being affected by sleep disruption.
6. Work with your physician to select the appropriate treatment pathway, whether that is CPAP therapy, an oral appliance, lifestyle modifications, or monitoring while newer pharmacological options like sulthiame move through clinical trials. CPAP is not part of the longevity membership: in Florida, Texas, Virginia and Maryland, Dumbo Health offers a separate CPAP plan from $59 a month that includes the machine, a mask fitted to your face, resupply and a care team.
7. Retest biomarkers at the 6-month mark through your membership to measure whether treatment is reducing inflammatory markers, improving metabolic indicators, and lowering your SleepLongevityAge score.

After completing these steps, you have a closed-loop system: diagnosis, treatment, and longitudinal biomarker verification that your intervention is actually working at the biological level.

Checklist Before Starting

• Confirm you are experiencing symptoms such as daytime fatigue, observed breathing pauses, loud snoring, morning headaches, or waking with a dry mouth
• Check where you live: the longevity membership is available in 49 states plus Washington DC (not Rhode Island), while the at-home sleep apnea test and CPAP care are available in Florida, Texas, Virginia and Maryland
• Check your HSA or FSA account: the Core and Concierge longevity memberships are HSA and FSA eligible

• Complete the free quiz to receive a personalized recommendation
• Set aside one morning for a fasting blood draw at a Quest Diagnostics location in your area
• If you use a wearable device (Oura, Whoop, Garmin), prepare to connect it for optional data integration into your SleepLongevityAge score
• Review the membership plans and lock in early-member pricing if available: the Core plan is $0.99 a day ($365 a year), and the Concierge plan is $300 a month ($3,600 a year) for early members

KEY TAKEAWAY: The path from suspected sleep apnea to understanding its biological aging impact is a structured 7-step process that starts with an assessment and ends with longitudinal biomarker tracking through Dumbo Health.

Before making any decision about sleep apnea treatment, it helps to separate what is established science from what is commonly misunderstood.

Common Myths About Sleep Apnea Medications and Epilepsy Drugs Debunked

MYTH: An epilepsy drug can completely replace CPAP for sleep apnea.

FACT: Sulthiame reduced the apnea-hypopnea index by approximately 20 to 30 percent in the phase 2b trial, compared to CPAP's 80 to 95 percent reduction. No pharmacological treatment currently matches the effectiveness of consistent CPAP use. The American Academy of Sleep Medicine continues to recommend positive airway pressure as first-line therapy for moderate to severe obstructive sleep apnea.

MYTH: If you do not snore, you do not have sleep apnea.

FACT: Upper-airway resistance syndrome and mild obstructive sleep apnea can occur without audible snoring. According to the National Heart, Lung, and Blood Institute, sleep apnea symptoms also include excessive daytime sleepiness, morning headaches, and observed breathing pauses. Some people, particularly women and younger adults, present with fatigue and sleep deprivation symptoms rather than classic snoring.

MYTH: Sleep apnea only affects your sleep quality, not your overall health or aging.

FACT: Untreated obstructive sleep apnea drives measurable biological aging through intermittent hypoxia, chronic inflammation (elevated cytokines), metabolic disruption (insulin resistance), and cardiovascular strain (hypertension, altered heart rhythm). The National Institute on Aging recognizes that biological age can diverge significantly from chronological age, and sleep quality is one of the modifiable factors that influences this gap.

MYTH: Carbonic anhydrase inhibitors are dangerous and experimental.

FACT: Carbonic anhydrase inhibitors including sulthiame and acetazolamide have been used clinically for decades. Sulthiame has been prescribed for epilepsy in Europe since the 1960s with a well-documented safety profile. Its application to sleep apnea is new, but the drug itself is not experimental. What is investigational is the specific use of sulthiame for obstructive sleep apnea, which still requires phase 3 clinical trial data and regulatory approval.

MYTH: You need an in-lab polysomnogram to get a reliable sleep apnea diagnosis.

FACT: While polysomnography remains the gold standard for comprehensive sleep assessment, home sleep apnea testing has become a validated diagnostic pathway for adults with a moderate to high pretest probability of obstructive sleep apnea. The Mayo Clinic notes that home tests effectively measure airflow, breathing effort, and blood oxygen levels. Dumbo Health's $149 at-home test provides physician-reviewed AHI and oxygen data without requiring an in-lab polysomnogram for initial diagnosis.

KEY TAKEAWAY: The most common misconceptions about sleep apnea medications involve overestimating drug efficacy, underestimating the systemic health consequences of untreated sleep apnea, and believing that diagnosis requires expensive in-lab testing.

With the myths cleared, the broader picture of where pharmacological sleep apnea treatment is headed becomes clearer.

What Comes Next: The Future of Pharmacological Sleep Apnea Treatment

Sulthiame is one of several drug candidates for obstructive sleep apnea, and the treatment landscape is evolving rapidly. AD109 (Apnimed), a nightly pill, is further along: its new drug application was accepted by the FDA in July 2026, with a target decision date of February 28, 2027. It is not yet approved.

The Pipeline Beyond Sulthiame

Researchers are exploring multiple pharmacological targets for sleep apnea beyond carbonic anhydrase inhibition. These include drugs that increase upper airway muscle tone during sleep, medications that raise the arousal threshold so the brain tolerates mild oxygen changes without triggering disruptive awakenings, and combination therapies that address multiple points in the PALM scale simultaneously.

GLP-1 based medications have also entered the picture. Tirzepatide (Zepbound) was approved by the FDA in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, the first drug approved for sleep apnea itself. It works mainly through weight loss.

Transcranial magnetic stimulation, currently used in research settings to study cortical excitability and brain function, is another area where investigators are exploring whether modulating brain activity during sleep could alter respiratory drive and arousal patterns. This remains early-stage research with no approved clinical application for sleep apnea.

Why Biomarker Tracking Matters Regardless of Treatment

Whether the eventual treatment is CPAP, sulthiame, a GLP-1 agonist, a surgical intervention, or some combination, the critical gap in current clinical practice is the absence of longitudinal biological aging data tied to sleep quality. A polysomnogram tells you what happened during one night of sleep. A blood pressure reading tells you one moment in time. Neither tells you whether your sleep disorder is accelerating your biological age over months and years.

This is the gap that Dumbo Health's sleep longevity membership is designed to close. By testing 51 to 103 biomarkers twice a year and computing a SleepLongevityAge score, the program provides the longitudinal data needed to evaluate whether any given treatment, current or future, is actually moving the needle on biological aging. The offering library includes add-on specialty packs like the Circadian and Stress pack ($269, covering morning cortisol and a 4-point salivary cortisol curve) and the Advanced Longevity pack ($99, covering Omega-3 Index, RBC magnesium, and key fatty acids) that provide deeper resolution into the biological pathways most affected by sleep apnea.

For people interested in referring a friend or family member who may be struggling with undiagnosed sleep apnea or untreated sleep disruption, the referral program makes it easy to share access.

KEY TAKEAWAY: The pharmacological treatment pipeline for sleep apnea is expanding beyond sulthiame, but regardless of which treatment becomes standard, longitudinal biomarker tracking is the only way to verify that treatment is reversing the biological aging caused by sleep disruption.

Conclusion

Sulthiame represents a genuine shift in how the medical community approaches obstructive sleep apnea treatment. For the first time, a well-studied epilepsy medication has demonstrated meaningful reductions in breathing interruptions and improvements in overnight oxygenation in a rigorous clinical trial. But the drug is not yet approved for sleep apnea, it does not replace CPAP for those who tolerate it, and the real question is not just whether your AHI improves but whether your biological age responds.

That is why the most forward-looking approach combines accurate sleep apnea diagnosis with longitudinal biomarker tracking. The Dumbo Health sleep quiz is a free starting point that takes minutes and requires no insurance, no prior authorization, and no commitment. Early members lock in the Core plan at $0.99 a day for life, with HSA and FSA eligibility, giving you the data to measure whether your sleep is aging you faster than it should.

Frequently Asked Questions About Epilepsy Drug for Sleep Apnea

What is sulthiame and why is it being studied as a treatment for sleep apnea?

Sulthiame is an antiepileptic medication, sold under the brand name Ospolot, that has been used for decades to treat certain forms of epilepsy. Researchers are now investigating it as a potential pharmacological treatment for obstructive sleep apnea because of its ability to act as a carbonic anhydrase inhibitor, a mechanism that appears to stabilise breathing during sleep. Early clinical trial results presented at the European Respiratory Society Congress 2024 showed that sulthiame reduced breathing interruptions and improved oxygen levels overnight in adults with obstructive sleep apnea. It remains an investigational drug for this use and is not yet approved as a sleep apnea treatment.

How does sulthiame work to reduce obstructive sleep apnea?

Sulthiame appears to work through several mechanisms relevant to obstructive sleep apnea. As a carbonic anhydrase inhibitor, it influences respiratory control by affecting how the brain and body sense oxygen and carbon dioxide. This action is thought to reduce loop gain, which is the tendency of the respiratory control system to overreact and cause unstable breathing patterns during sleep. Sulthiame may also improve upper airway muscle responsiveness and reduce airway collapse. Researchers at the University of Gothenburg and Sahlgrenska University Hospital have proposed that by lowering cortical excitability and acting on respiratory pauses at a neurological level, sulthiame addresses some of the underlying drivers of obstructive sleep apnea beyond simple airway obstruction.

What did the clinical trial of sulthiame for sleep apnea find?

Phase 2b trial results for sulthiame in obstructive sleep apnea were presented at the European Respiratory Society Congress 2024 by researchers including Jan Hedner from Sahlgrenska University Hospital in Gothenburg. The trial, conducted across several European countries including Belgium, Czech Republic, France, Germany, and Spain, showed that sulthiame significantly reduced the apnea-hypopnea index compared to placebo. Participants also showed improvements in oxygen desaturation. Daytime sleepiness, measured with the Epworth Sleepiness Scale, was a secondary measure and showed at most a trend toward improvement. The American Academy of Sleep Medicine notes that AHI and oxygen saturation are primary measures in evaluating sleep apnea severity, making these outcomes clinically meaningful if confirmed in larger studies.

Is sulthiame approved to treat sleep apnea in the United States or Europe?

Sulthiame is not currently approved as a treatment for obstructive sleep apnea in the United States or Europe. It is an investigational drug in this context, meaning it is being studied in clinical trials but has not yet received regulatory clearance specifically for sleep apnea. It is licensed in some European countries as an antiepileptic medication under the name Ospolot. Anyone interested in sulthiame for sleep apnea should speak with a sleep physician or specialist about trial availability and whether it might be appropriate for their individual situation. A healthcare professional can help determine whether experimental treatments are suitable given a person's full medical history.

What is the apnea-hypopnea index and why does it matter for sleep apnea treatment?

The apnea-hypopnea index, commonly called the AHI, measures the average number of breathing interruptions per hour of sleep. These interruptions include both apneas, which are complete pauses in breathing, and hypopneas, which are partial reductions in airflow. A higher AHI indicates more severe obstructive sleep apnea. According to the American Academy of Sleep Medicine, an AHI of 5 to 14 is generally classified as mild, 15 to 29 as moderate, and 30 or above as severe. Clinical trials evaluating new treatments like sulthiame use AHI reduction as a primary outcome measure because it directly reflects how well a treatment is controlling breathing disruptions during sleep.

Could sulthiame replace CPAP therapy for sleep apnea?

It is too early to say whether sulthiame could replace CPAP therapy for sleep apnea. Continuous positive airway pressure remains the most established and widely recommended treatment for moderate to severe obstructive sleep apnea, and no pharmacological treatment has yet been approved to replace it. The sulthiame trials suggest meaningful reductions in AHI and improvements in oxygenation, but long-term safety, durability of effect, and outcomes across different patient profiles have not yet been fully established. Sulthiame may eventually serve as an alternative for patients who cannot tolerate CPAP, or as a complementary approach, but treatment decisions should always be made with a qualified clinician based on individual test results and health history.

Who might benefit most from a drug-based approach to treating obstructive sleep apnea?

Adults who experience significant difficulty tolerating CPAP therapy may be among those who could benefit most from a pharmacological approach if effective options become available. CPAP adherence is a recognised clinical challenge; some patients find the mask uncomfortable, experience claustrophobia, or find the noise disruptive. Other potential candidates for drug-based therapy could include people with obstructive sleep apnea driven primarily by respiratory control instability rather than structural airway collapse, as sulthiame's mechanism appears particularly relevant to this phenotype. A sleep physician using tools such as the PALM scale, which categorises obstructive sleep apnea by underlying mechanism, can help identify whether a patient's physiology might respond well to pharmacological treatment.

What are the known side effects of sulthiame?

In its established use as an antiepileptic medication, sulthiame has a documented safety profile. Common side effects associated with carbonic anhydrase inhibitors as a class include headaches, tingling sensations, and changes in breathing pattern. Because sulthiame acts on carbonic anhydrase, it can also affect metabolic processes. In the sleep apnea clinical trials, researchers monitored for these effects carefully, and the drug was generally described as well-tolerated at the doses studied. However, because sulthiame is still investigational for sleep apnea, its full side effect profile in this patient population and at the doses required for respiratory effects is still being established. Anyone considering this treatment should discuss risks with a qualified clinician.

What is the connection between carbonic anhydrase inhibition and breathing during sleep?

Carbonic anhydrase is an enzyme involved in regulating the balance of carbon dioxide and bicarbonate in the blood, which directly influences respiratory drive. By inhibiting this enzyme, sulthiame shifts the body's acid-base balance in a way that encourages deeper and more regular breathing. This can reduce the loop gain in the respiratory control system, making breathing more stable during sleep and less prone to the cyclical pauses and arousals that characterise obstructive sleep apnea. Researchers in pulmonary medicine and respiratory control have investigated carbonic anhydrase inhibitors for sleep-disordered breathing for several years, and sulthiame's particular profile makes it a candidate worth studying in this context.

How is obstructive sleep apnea diagnosed, and can a home sleep test detect it?

Obstructive sleep apnea is diagnosed by measuring breathing, oxygen levels, heart rhythm, and muscle activity during sleep. The gold-standard diagnostic test is polysomnography, also called a polysomnogram or in-lab sleep study, which records a comprehensive set of sleep and respiratory measurements overnight in a clinical setting. Home sleep apnea tests, or HSATs, are a validated and widely used alternative for adults suspected of having moderate to severe obstructive sleep apnea without significant complicating conditions. The American Academy of Sleep Medicine supports the use of home sleep testing in appropriate clinical populations. An at-home sleep apnea test measures breathing interruptions, oxygen desaturation, and airflow to generate an apnea-hypopnea index.

How does an at-home sleep apnea test work?

An at-home sleep apnea test is an FDA-cleared device worn overnight in the patient's own home. It typically measures airflow, respiratory effort, and oxygen saturation using sensors placed on the finger, chest, and around the nose or mouth. The recorded data is then reviewed by a physician who uses it to calculate the apnea-hypopnea index and assess oxygen desaturation patterns. Results are typically available within 48 hours of the test night. Dumbo Health offers an at-home sleep apnea test for $149 as a one-time purchase, with physician diagnosis typically within 48 hours and transparent, cash-pay pricing.

What is REM sleep and why does it matter for obstructive sleep apnea?

REM sleep, or rapid eye movement sleep, is the sleep stage associated with vivid dreaming and a natural reduction in muscle tone throughout the body, including the muscles of the upper airway. This reduction in muscle activity makes the airway more susceptible to collapse during REM sleep, which is why obstructive sleep apnea is often more severe during this stage. REM-related obstructive sleep apnea is a recognised clinical subtype. Treatments that improve upper airway muscle responsiveness or reduce airway collapsing may be particularly relevant during REM sleep. Sulthiame's proposed mechanisms, including effects on upper airway muscles and respiratory control, are being evaluated partly in the context of REM-stage breathing disruptions.

Can epilepsy surgery resolve obstructive sleep apnea in some patients?

In rare cases, epilepsy surgery has been associated with improvement or resolution of obstructive sleep apnea, particularly when seizure activity or epilepsy-related neurological changes were contributing to breathing instability during sleep. The relationship between epilepsy and obstructive sleep apnea is complex. Seizures can disrupt sleep architecture, and antiepileptic medications can affect respiratory drive and muscle tone. Conversely, sleep deprivation caused by untreated obstructive sleep apnea is a recognised trigger for seizures in people with epilepsy. The bidirectional relationship between these two conditions is an active area of research. A neurologist and sleep specialist should collaborate when both epilepsy and obstructive sleep apnea are present.

How does sleep apnea affect oxygen levels and why does intermittent hypoxia matter?

Obstructive sleep apnea causes repeated drops in blood oxygen levels, a process called oxygen desaturation or intermittent hypoxia. Each time the airway collapses and breathing pauses, oxygen saturation falls. When breathing resumes, oxygen levels recover, but the cycle repeats throughout the night. According to the National Heart, Lung, and Blood Institute, chronic intermittent hypoxia caused by untreated sleep apnea contributes to high blood pressure, cardiovascular strain, inflammatory processes, insulin resistance, and metabolic syndrome over time. Measuring how far oxygen levels drop overnight, and how frequently, is a key part of evaluating sleep apnea severity and the potential long-term health consequences of leaving it untreated.

What is loop gain and how does it relate to obstructive sleep apnea?

Loop gain is a term from engineering that describes how sensitively a control system responds to a disturbance. In respiratory medicine, loop gain refers to how strongly the breathing control system reacts when breathing is temporarily disrupted. People with high loop gain have an oversensitive respiratory control system that tends to overcorrect after a breathing pause, causing oscillating patterns of breathing that sustain or worsen obstructive sleep apnea. Identifying loop gain as a contributor to a patient's sleep apnea is part of phenotyping the condition using tools such as the PALM scale, which evaluates pharyngeal critical closing pressure, arousal threshold, loop gain, and muscle responsiveness. Sulthiame is thought to reduce loop gain, which is part of the rationale for studying it in obstructive sleep apnea.

What is the Epworth Sleepiness Scale and how is it used in sleep apnea care?

The Epworth Sleepiness Scale is a validated self-reported questionnaire used to measure daytime sleepiness. It asks a person to rate how likely they are to fall asleep in eight everyday situations, producing a total score that helps clinicians assess the subjective burden of sleep deprivation and sleep-disordered breathing. Scores above 10 are generally considered to indicate excessive daytime sleepiness warranting clinical evaluation, according to the Sleep Foundation. In clinical trials for obstructive sleep apnea treatments, including the sulthiame trials, the Epworth Sleepiness Scale is used alongside the apnea-hypopnea index and oxygen saturation measures to capture the patient-experienced impact of treatment. Fatigue and daytime sleepiness are among the most common symptoms reported by people with untreated obstructive sleep apnea.

Can untreated sleep apnea affect blood pressure and cardiovascular health?

Yes. Untreated obstructive sleep apnea is associated with elevated blood pressure, particularly hypertension that is resistant to standard medications. The repeated cycles of oxygen desaturation, arousal, and sympathetic nervous system activation that occur with each breathing interruption place chronic strain on the cardiovascular system. The CDC recognises sleep apnea as a risk factor for hypertension, heart disease, and stroke. Effective treatment with CPAP therapy or, if future evidence supports it, pharmacological options like sulthiame, may help reduce these cardiovascular risks. A healthcare professional can assess cardiovascular risk factors and help determine the most appropriate treatment pathway based on individual test results and health history.

How does CPAP therapy work for obstructive sleep apnea?

Continuous positive airway pressure, or CPAP, therapy works by delivering a steady stream of pressurised air through a mask worn over the nose or mouth during sleep. This constant positive airway pressure acts as a pneumatic splint, keeping the upper airway open and preventing the airway collapse that causes obstructive sleep apnea. CPAP is widely considered the most effective treatment for moderate to severe obstructive sleep apnea. Adherence is critical; the benefit of CPAP depends on consistent nightly use. In Florida, Texas, Virginia and Maryland, Dumbo Health offers a CPAP plan from $59 a month that includes the machine, a mask fitted to your face, resupply and a care team. It is separate from the longevity membership.

What happens if someone with sleep apnea cannot tolerate a CPAP mask?

Some people find CPAP masks uncomfortable, noisy, or difficult to use consistently. Alternative treatments for obstructive sleep apnea include oral appliances, which reposition the jaw to keep the airway open, upper airway surgery, weight management, positional therapy for position-dependent sleep apnea, and, in some cases, device-based therapies such as hypoglossal nerve stimulation, sometimes described as a pacemaker for the tongue. Research into pharmacological options like sulthiame is motivated in part by the significant number of patients who struggle with CPAP adherence. A sleep physician can evaluate which alternative or combination treatment is most appropriate based on anatomy, sleep apnea severity, and underlying physiological factors.

What is hypoglossal nerve stimulation and how does it compare to CPAP for sleep apnea?

Hypoglossal nerve stimulation, sometimes referred to as a tongue pacemaker, is an implantable device that delivers mild electrical stimulation to the hypoglossal nerve during sleep, prompting the tongue and upper airway muscles to move forward and keep the airway open. It is approved for adults with moderate to severe obstructive sleep apnea who cannot tolerate CPAP therapy and who meet specific anatomical criteria. Unlike CPAP, it does not require a mask or external device to be worn during sleep. It is a surgical procedure and carries different risks and costs. A sleep physician can assess whether this therapy is an appropriate option based on the results of polysomnography and a clinical evaluation including measures such as Mallampati classification and tonsil grading.

How does sleep apnea interact with epilepsy?

Sleep apnea and epilepsy have a well-recognised bidirectional relationship. Untreated obstructive sleep apnea disrupts sleep architecture, fragments non-REM and REM sleep, and causes chronic sleep deprivation, all of which are recognised triggers for seizures in people with epilepsy. Conversely, seizure activity and some antiepileptic medications can affect respiratory drive, muscle tone, and upper airway stability during sleep. Some research suggests that effective treatment of obstructive sleep apnea in people with epilepsy may improve seizure control. The investigation of sulthiame as a treatment for sleep apnea adds an interesting dimension to this relationship, as an antiepileptic medication may turn out to have direct therapeutic effects on sleep-disordered breathing through its carbonic anhydrase inhibition and effects on respiratory control.

Can sleep apnea affect commercial drivers and their ability to maintain a CDL?

Yes. The FMCSA recognises obstructive sleep apnea as a medical condition that can impair driving safety through excessive daytime sleepiness, reduced reaction time, and impaired concentration. A certified medical examiner may refer a commercial driver for sleep apnea evaluation as part of a DOT physical if risk factors such as high body mass index, hypertension, or reported symptoms are present. If diagnosed and treated effectively, many drivers with obstructive sleep apnea can continue to operate commercially. Documented CPAP adherence is typically required as part of ongoing certification. A certified medical examiner makes DOT certification decisions, not Dumbo Health, but Dumbo Health can support sleep apnea testing and care documentation for CDL drivers in Florida, Texas, Virginia and Maryland.

How much does an at-home sleep apnea test cost, and is insurance required?

Dumbo Health offers an at-home sleep apnea test for $149 as a one-time purchase, with no insurance required and no prior authorizations. The test includes the FDA-cleared home sleep test device and one night of testing, with physician diagnosis typically within 48 hours. The test is available in Florida, Texas, Virginia and Maryland. People who want a broader picture of how sleep may be affecting their biological aging can also explore the Dumbo Health longevity membership plans, which combine biomarker testing with physician review and optional wearable data integration starting at $0.99 a day for early members.

What biomarkers are relevant to sleep apnea and its long-term health effects?

Several biomarkers reflect the systemic health consequences of untreated obstructive sleep apnea. High-sensitivity C-reactive protein, or hs-CRP, is a marker of systemic inflammation that tends to be elevated in people with poorly controlled sleep apnea. HbA1c and fasting glucose reflect glucose metabolism and insulin resistance, both of which are associated with sleep-disordered breathing. ApoB reflects cardiovascular risk. Cortisol and DHEA-S reflect the hormonal stress burden that chronic sleep deprivation and intermittent hypoxia can impose. Testosterone is often reduced in men with untreated severe sleep apnea. Dumbo Health's sleep longevity biomarker panel covers metabolic, inflammatory, hormonal, and cardiovascular markers to help track how sleep may be affecting biological health over time.

What is SleepLongevityAge and how is it calculated?

SleepLongevityAge is a proprietary metric developed by Dumbo Health to estimate how sleep quality and sleep-related health factors are influencing a person's biological aging. It is calculated from blood biomarker results covering metabolic, inflammatory, hormonal, and cardiovascular health, and can incorporate optional wearable data from devices such as Oura, Whoop, or Garmin. The score is reviewed by physicians and is designed to show whether sleep patterns appear to be accelerating or slowing biological aging relative to a person's chronological age. A SleepLongevityAge score is a wellness and screening tool, not a clinical diagnosis, and any abnormal results should be reviewed with a healthcare professional. Learn more about Dumbo Health longevity.

How can I find out whether my sleep might be affecting my biological age?

The free Dumbo Health sleep quiz is a practical starting point. It helps identify whether biomarker testing, a home sleep apnea test, or physician review may be a reasonable next step based on your individual symptoms, risk factors, and health goals. Testing locations for blood draws are available through a national lab network; you can find a testing location near you. A physician can help interpret what your SleepLongevityAge score and biomarker results mean for your individual health, and guide any decisions about further testing or treatment.